Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
February 6, 2012
- Eisai Says Impact from Generic Versions of Aricept Insignificant
February 3, 2012
- Eisai's Apr-Dec Sales Down 17% on 50% Drop in Aricept Sales
February 3, 2012
- Pfizer to Offer Financial, Technical Support for Early Stage Development to External Institution
February 3, 2012
- Apr-Dec Sales Up 4%, Profits Show 2-Digit Increase due to Growth in Vesicare: Astellas
February 3, 2012
- Chugai to Restructure Marketing Div. to Achieve Targets in “Sunrise 2012” Plan
February 3, 2012
- New Granule Formulation of Fosrenol Obtains Approval: Bayer Yakuhin
February 3, 2012
- Janssen Files Application for Additional Subcutaneous Administration of Velcade
February 2, 2012
- Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
February 2, 2012
- Astellas, UCB Form Partnership for Rheumatoid Arthritis Treatment Awaiting Approval
February 2, 2012
- Kyowa Kirin Sees Nesp as Core of Its Asian Strategy: President Matsuda
February 2, 2012
- Maruho, Asahi Kasei Pharma File Application for Add’l Indication of Herpes Simplex for Famvir
February 2, 2012
- Nycomed Acquisition Contributes to 4.3% Growth in Sales for April-December 2011: Takeda
February 2, 2012
- Daiichi Sankyo Says “No Major Impact” from Ranbaxy’s Relinquishment of Marketing Exclusivity
February 1, 2012
- Shuichi Watanabe to Become President, Sadatake Kumakura Chairman: Medipal HD
February 1, 2012
- Apr-Dec Net Profits Down 78% due to Ranbaxy Settlement Fee: Daiichi Sankyo
February 1, 2012
- Kyowa Hakko Kirin Withdraws Application for Additional Indication for Nesp
February 1, 2012
- Kyowa Kirin Development Chief Hanai Set to Become Company President
February 1, 2012
- Apr-Dec Sales Drop 1.2% due to Impact of Great East Japan Earthquake: MTPC
February 1, 2012
- Shared Awareness of Goals Needed in Industry-Academia Collaborations: Dr Teshirogi of Shionogi
February 1, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…